We believe Carl Zeiss Meditec is in excellent financial health. At the end of fiscal-year 2023, the company had a cash and equivalents balance of 880 million euros with little to no debt.

Hyundai Mobis confirmed the two companies have agreed to jointly develop a new ‘Holographic Windshield Display' ...

Earnings Per Share (TTM) A company's net income for the trailing twelve month period expressed as a dollar amount per fully diluted shares outstanding. Market Capitalization Reflects the total ...

Winner of the 2023 Optician Awards Lens Award, Carl Zeiss Vision, speaks to Emma White about sustainability, product ...

Most readers would already be aware that Carl Zeiss Meditec's (ETR:AFX) stock increased significantly by 19% over ...

Carl Zeiss Meditec is one of the largest medical technology companies in the world, and it operates in two segments: ophthalmic devices, or OPT, and microsurgery, or MCS. OPT makes up roughly 75% ...

Carl Zeiss Meditec AG (ETR:AFX), is not the largest company out there, but it led the XTRA gainers with a relatively large price hike in the past couple of weeks. Shareholders may appreciate the ...

In the age of mobile phones, ZEISS’ expertise in camera lenses has generated valuable partnerships with tech companies like ...

ZEISS VisioGen offers a cutting-edge, AI-driven solution designed to enhance refractive patient communication and streamline ...

Carl Zeiss Meditec AG (ISIN: DE0005313704) is one of the world's leading medical technology companies and is included in the German MDAX and TecDAX stock indices. The company supplies innovative ...

Carl Zeiss Meditec appears to be overvalued by 25% at the moment, based on our discounted cash flow valuation. The stock is currently priced at €70.85 on the market compared to our intrinsic value of ...

ZEISS VisioGen offers a cutting-edge, AI-driven solution designed to enhance refractive patient communication and streamline ...